Understanding how certain immune cells affect glioblastoma progression
Official title: Role of myeloid-derived suppressor cells in local and systemic immunosuppression in glioblastoma
Funded at University of Miami School of Medicine · NIH-11046531 · Data updated 2026-11-12
This study is looking at how certain immune cells called myeloid-derived suppressor cells (MDSCs) affect glioblastoma, a tough brain cancer, and how these cells might differ between men and women, with the hope of finding better ways to help patients respond to treatments.
Quick facts
| Grant type | NIH-funded research |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Miami School of Medicine NIH-funded |
| Lab location | 1 site (Coral Gables, United States) |
| Project start | March 7, 2023 |
| Project end | February 28, 2026 |
| Funding year | 2025 |
| Award (this year) | $248,998 |
| NIH project number | 5R00CA248611-05 |
| Project ID | NIH-11046531 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with glioblastoma, particularly those who may not have responded well to current therapies.
✕Less likely to help
Patients with glioblastoma who are not eligible for immunotherapy or those with other types of brain tumors may not benefit from this research.
What this research studies
This research investigates the role of myeloid-derived suppressor cells (MDSCs) in glioblastoma, a highly aggressive brain tumor. It aims to understand how different types of MDSCs contribute to the tumor's ability to evade the immune system and promote its growth. By examining the variations in MDSC populations between male and female patients, the study seeks to uncover potential therapeutic targets that could enhance the effectiveness of existing treatments. Patients may benefit from insights that could lead to improved immunotherapy strategies tailored to their specific immune profiles.
Why it matters
Potential benefit: If successful, this research could lead to more effective treatments for glioblastoma by targeting the immune suppression caused by MDSCs.
How similar studies have gone: Previous research has shown that targeting immune suppression in tumors can improve treatment outcomes, suggesting that this approach may hold promise.
Where this research is happening
-
University of Miami School of Medicine
Coral Gables, United States Active
Researchers
- Principal investigator: Bayik Watson, Defne — University of Miami School of Medicine
- Study coordinator: Bayik Watson, Defne
Related research
Other NIH-funded projects on the same topics.
-
AHR-driven immunosuppression in glioblastoma and new therapeutic targets
A personalized cancer study aims to understand why glioblastoma suppresses the immune system and to find ways to boost anti-tumor immunity in patients with this brain tumor.
-
Understanding and Overcoming T cell Immunosuppression in Glioblastoma (GBM)
A large research program is looking at how glioblastoma tumors weaken immune responses and how to boost immune cells to fight GBM.
-
How the protein CHI3L1 weakens immune attacks in glioblastoma
Seeing if blocking CHI3L1 helps the immune system attack glioblastoma in adults with this brain tumor.
-
Investigating how a protein affects immune response in brain tumors
This study is looking at how glioblastoma, a tough brain tumor, manages to escape the body's immune defenses, focusing on a protein called CHI3L1, to find new ways to help the immune system fight the tumor better.
-
Exploring ways to enhance T cell activity against glioblastoma
This study is looking at ways to make treatments for glioblastoma, a tough type of brain cancer, work better by focusing on the immune system's T cells, and it aims to find new ways to boost these cells to help patients feel better.
-
Investigating how immune cells affect glioblastoma growth
This study is looking at how certain immune cells in the brain, called tumor-associated macrophages, affect glioblastoma and how we can use this information to create new treatments that help the immune system fight the tumor better.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.